News
Loss of S$0.001 per share (compared to loss of S$0.001 in 1Q 2023)
Biolidics (Catalyst: 8YY) Results for the first quarter of 2024
Main financial results
-
Revenue: S$137.0 thousand (down 88% compared to 1Q 2023).
-
Net loss: S$760.0 thousand (loss increased by 122% compared to 1Q 2023).
-
Loss of S$0.001 per share (in line with 1Q 2023).
earnings and income history
All numbers shown in the chart above are for the period of the last 12 months (TTM)
Biolidics shares are up 10.0% from the previous week.
Risk analysis
We should say we discovered 7 warning signs for Biolidics (6 should not be ignored!) that you should know before investing here.
Do you have feedback on this article? Worried about the content? Get in touch with us directly. Alternatively, email the editorial team (at) Simplywallst.com.
This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to bring you long-term focused analysis driven by fundamental data. Please note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St has no position in any of the stocks mentioned.